CN112057601B - 一种活性益生菌冻干粉制备方法及在皮肤和妇科疾病中的应用 - Google Patents
一种活性益生菌冻干粉制备方法及在皮肤和妇科疾病中的应用 Download PDFInfo
- Publication number
- CN112057601B CN112057601B CN202011249123.0A CN202011249123A CN112057601B CN 112057601 B CN112057601 B CN 112057601B CN 202011249123 A CN202011249123 A CN 202011249123A CN 112057601 B CN112057601 B CN 112057601B
- Authority
- CN
- China
- Prior art keywords
- freeze
- thalli
- drying
- percent
- probiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 62
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 62
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 44
- 239000000843 powder Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 201000010099 disease Diseases 0.000 title abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 7
- 238000004108 freeze drying Methods 0.000 claims abstract description 28
- 239000003223 protective agent Substances 0.000 claims abstract description 23
- 241000186660 Lactobacillus Species 0.000 claims abstract description 20
- 239000002068 microbial inoculum Substances 0.000 claims abstract description 20
- 241001052560 Thallis Species 0.000 claims abstract description 17
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 17
- 206010046914 Vaginal infection Diseases 0.000 claims abstract description 15
- 201000008100 Vaginitis Diseases 0.000 claims abstract description 12
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 11
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 11
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 11
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 9
- 238000007710 freezing Methods 0.000 claims abstract description 7
- 230000008014 freezing Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 7
- 241000894006 Bacteria Species 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 18
- 108010010803 Gelatin Proteins 0.000 claims description 17
- 239000008273 gelatin Substances 0.000 claims description 17
- 229920000159 gelatin Polymers 0.000 claims description 17
- 235000019322 gelatine Nutrition 0.000 claims description 17
- 235000011852 gelatine desserts Nutrition 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 239000000047 product Substances 0.000 claims description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 9
- 239000002504 physiological saline solution Substances 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 235000020183 skimmed milk Nutrition 0.000 claims description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 6
- 239000011265 semifinished product Substances 0.000 claims description 6
- 229940073490 sodium glutamate Drugs 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 230000003385 bacteriostatic effect Effects 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 238000000465 moulding Methods 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 239000007909 solid dosage form Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 239000008297 liquid dosage form Substances 0.000 claims description 2
- 229920001503 Glucan Polymers 0.000 claims 2
- 239000006208 topical dosage form Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 15
- 230000004083 survival effect Effects 0.000 abstract description 9
- 238000012216 screening Methods 0.000 abstract description 4
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 12
- 210000001215 vagina Anatomy 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 230000005856 abnormality Effects 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 4
- 229960000282 metronidazole Drugs 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000008852 Hyperoxaluria Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 208000037009 Vaginitis bacterial Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241000193798 Aerococcus Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 241000379991 Anaerococcus Species 0.000 description 1
- FOQFHANLUJDQEE-GUBZILKMSA-N Arg-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)N)C(=O)N[C@@H](CS)C(=O)O FOQFHANLUJDQEE-GUBZILKMSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- ARPVSMCNIDAQBO-YUMQZZPRSA-N Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O ARPVSMCNIDAQBO-YUMQZZPRSA-N 0.000 description 1
- CJWANNXUTOATSJ-DCAQKATOSA-N Glu-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N CJWANNXUTOATSJ-DCAQKATOSA-N 0.000 description 1
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GETCJHFFECHWHI-QXEWZRGKSA-N Met-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCSC)N GETCJHFFECHWHI-QXEWZRGKSA-N 0.000 description 1
- 241000187708 Micromonospora Species 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 208000002389 Pouchitis Diseases 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- ZHDQRPWESGUDST-JBACZVJFSA-N Trp-Phe-Gln Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C1=CC=CC=C1 ZHDQRPWESGUDST-JBACZVJFSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- PGBMPFKFKXYROZ-UFYCRDLUSA-N Val-Tyr-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N PGBMPFKFKXYROZ-UFYCRDLUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940041984 dextran 1 Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 244000000072 vaginal pathogen Species 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Abstract
Description
时间/月 | 4 ℃存活率% | 25 ℃存活率% |
2 | 99.57±1.31% | 99.13±1.03% |
4 | 99.01±1.02% | 98.76±1.31% |
6 | 98.53±1.55% | 97.43±1.52% |
8 | 98.01±1.11% | 94.01±0.96% |
10 | 97.46±1.19% | 92.33±1.24% |
12 | 96.83±2.01% | 90.17±1.46% |
组别 | 给药前 | 给药后 |
模型组(作为对照,不给药) | 1.47±0.21(×10<sup>3</sup>CFU/μL) | 3.79±0.48(×10<sup>3</sup>CFU/μL) |
复方甲硝唑对照组 | 1.26±0.09(×10<sup>3</sup>CFU/μL) | 0.91±0.33(×10<sup>3</sup>CFU/μL) |
实施例2菌剂实验治疗组 | 1.35±0.17(×10<sup>3</sup>CFU/μL) | 1.16±0.11(×10<sup>2</sup>CFU/μL) |
实施例3菌剂治疗组 | 1.40±0.13(×10<sup>3</sup>CFU/μL) | 6.82±0.11(×10<sup>2</sup>CFU/μL) |
1天 | 2天 | 3天 | 4天 | 5天 | 6天 | 7天 | |
实施例2菌剂 | 无异常 | 无异常 | 无异常 | 无异常 | 无异常 | 无异常 | 无异常 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011249123.0A CN112057601B (zh) | 2020-11-11 | 2020-11-11 | 一种活性益生菌冻干粉制备方法及在皮肤和妇科疾病中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011249123.0A CN112057601B (zh) | 2020-11-11 | 2020-11-11 | 一种活性益生菌冻干粉制备方法及在皮肤和妇科疾病中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112057601A CN112057601A (zh) | 2020-12-11 |
CN112057601B true CN112057601B (zh) | 2021-02-05 |
Family
ID=73655689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011249123.0A Active CN112057601B (zh) | 2020-11-11 | 2020-11-11 | 一种活性益生菌冻干粉制备方法及在皮肤和妇科疾病中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112057601B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113621519B (zh) * | 2021-08-11 | 2023-07-18 | 河南农业大学 | 一种复合酵母冻干保护剂 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104043098A (zh) * | 2014-04-04 | 2014-09-17 | 广州舒泰生物技术有限公司 | 一种用于治疗妇女阴道炎的抗菌肽冻干制剂及制备方法 |
CN109224078A (zh) * | 2018-09-14 | 2019-01-18 | 孙静 | 益生菌滴剂粉剂软硬胶囊片剂及其益生菌素和在生产抗菌肽中的所有应用 |
CN110585246A (zh) * | 2019-09-22 | 2019-12-20 | 深圳市多微生保健食品有限公司 | 一种阴道抑菌制剂及其制备方法 |
CN111228458A (zh) * | 2020-03-24 | 2020-06-05 | 大连富勒烯药业有限公司 | 防治阴道炎症的外用生物制剂及其制备方法 |
CN111471623A (zh) * | 2020-04-21 | 2020-07-31 | 广东龙创基药业有限公司 | 三种乳杆菌的组合物及其用途 |
-
2020
- 2020-11-11 CN CN202011249123.0A patent/CN112057601B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104043098A (zh) * | 2014-04-04 | 2014-09-17 | 广州舒泰生物技术有限公司 | 一种用于治疗妇女阴道炎的抗菌肽冻干制剂及制备方法 |
CN109224078A (zh) * | 2018-09-14 | 2019-01-18 | 孙静 | 益生菌滴剂粉剂软硬胶囊片剂及其益生菌素和在生产抗菌肽中的所有应用 |
CN110585246A (zh) * | 2019-09-22 | 2019-12-20 | 深圳市多微生保健食品有限公司 | 一种阴道抑菌制剂及其制备方法 |
CN111228458A (zh) * | 2020-03-24 | 2020-06-05 | 大连富勒烯药业有限公司 | 防治阴道炎症的外用生物制剂及其制备方法 |
CN111471623A (zh) * | 2020-04-21 | 2020-07-31 | 广东龙创基药业有限公司 | 三种乳杆菌的组合物及其用途 |
Non-Patent Citations (3)
Title |
---|
乳酸维持正常阴道微生态的研究进展;董梦婷等;《中华微生物学和免疫学杂志》;20190430;第39卷(第4期);311-315 * |
抗菌肽:治疗阴道炎的研究;房师松等;《广东蚕业》;20101231;第44卷(第1期);41-45 * |
抗菌肽Maximin11阴道用凝胶的制备与评价;侯丽等;《中国新药杂志》;20191231;第28卷(第1期);81-86 * |
Also Published As
Publication number | Publication date |
---|---|
CN112057601A (zh) | 2020-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110016442B (zh) | 鼠李糖乳杆菌及其复合菌粉在防治阴道炎制品中的应用 | |
CN1100546C (zh) | 药用的微胶囊化乳芽孢杆菌 | |
CN102835657B (zh) | 用以抑制发炎反应及抗阴道炎的含乳酸菌食品组合物及医药组合物 | |
CN107815432B (zh) | 一种人用灭活乳酸菌制剂及其用途 | |
CN112342175B (zh) | 一种阴道健康益生菌组合物及其应用 | |
RU2536264C2 (ru) | Композиция для наружного применения на коже, содержащая соль и сахар в качестве активных ингредиентов, для предотвращения и лечения вагиноза, и ее применение | |
CN103409334B (zh) | 抑制阴道炎病原菌之乳酸杆菌及其用途 | |
CN109402002B (zh) | 一种加氏乳杆菌及其在制备预防早产药物中的应用 | |
CN116200306B (zh) | 一种鼠李糖乳酪杆菌LRa16及其在制备治疗生殖道感染的药物方面的用途和产品 | |
CN111084831A (zh) | 一种抑制阴道致病菌的抑菌组合物及其应用 | |
CN103157095B (zh) | 芸豆植物凝集素在制备人用药物中的应用及其药物组合物 | |
CN109985069B (zh) | 益生菌组合物及其用途 | |
CN114774315B (zh) | 鼠李糖乳杆菌菌株LRa05在制备增强免疫力制品和/或缓解湿疹制品方面的用途 | |
CN112057601B (zh) | 一种活性益生菌冻干粉制备方法及在皮肤和妇科疾病中的应用 | |
CN114921389A (zh) | 一种具有女性肠私处护理和乳腺抗炎功效的益生菌组合物及其应用 | |
TW201414481A (zh) | 使用硫代硫酸鹽以強化乳酸桿菌的抗-致病性作用之用途 | |
US20040022775A1 (en) | Methods of treating viral infections in mammals | |
CN113278548B (zh) | 卷曲乳杆菌及在生产改善人体阴道环境的产品中的应用 | |
KR101355441B1 (ko) | 질염 병원균의 증식을 억제하는 활성을 갖는 락토바실러스 존소니 에이취와이7042 및 이를 유효성분으로 함유하는 제품 | |
CN103191408A (zh) | 一种治疗阴道炎的药物组合物、凝胶剂及其用途 | |
CN113274414A (zh) | 一种修复和维持阴道微生态平衡的益生菌制剂 | |
CN111567807A (zh) | 抑制发炎反应和抗阴道炎的含鼠李糖乳杆菌组合物及应用 | |
CN105534948B (zh) | 一种可常温保存的阴道用活菌制剂及其制备方法 | |
TW201316996A (zh) | 抑制陰道炎病原菌之乳酸桿菌及其用途 | |
CN113041266B (zh) | 一株改善银屑病样小鼠病理特征的干酪乳杆菌及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231211 Address after: 100176 room 01-12, 1st floor, building 1, No.3, Yongchang North Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing Patentee after: Nuosa Union (Beijing) Biomedical Technology Co.,Ltd. Patentee after: Beijing Daxi Biotechnology Co.,Ltd. Address before: 1408, 14th floor, building 1, yard 5, Ronghua Middle Road, economic and Technological Development Zone, Daxing District, Beijing Patentee before: Beijing Daxi Biotechnology Co.,Ltd. |